The TME is then more infiltrated by CD45+ CD3+ total cells and CD45+ CD3+ CD8+ cytotoxic T cells, and this more inflamed environment enhances the efficacy of anti-PD-1 therapy on tumour cells [78]. This evidence concerns the gene PTPRC and neoplasm.